The ills inflicted by poor strategy

The ills inflicted by poor strategy Candice O’Sullivan

If brand managers adopt a policy of 'doing no harm', as doctors do, then strategies will be taken seriously and the outcomes will be the best possible, for the brand... Read more

Facebook and pharma in 2014

Facebook and pharma in 2014Stefan Marcus

Ten years on, Facebook remains an important channel through which pharma can engage with patients. What has been learned in that time and how have communication strategies evolved within the... Read more

'Efficiency-driven' M&A is here to stay, says Shire chief

'Efficiency-driven' M&A is here to stay, says Shire chiefAndrew McConaghie

Andrew McConaghie reports on contrasting views on 2014's merger and acquisition rollercoaster ride, and the forces propelling it. The annual pharma / biotech sector conference hosted by the Financial Times usually yields... Read more

AZ points to potential in cancer at strategy update

AZ points to potential in cancer at strategy updateStaff reporter

AstraZeneca (AZ) predicted yesterday that its "industry-leading" cancer portfolio would account for a quarter of its revenues in 2023 and is now considered its sixth growth platform.Just six months ago... Read more